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This common condition may have multisystem complications across the lifespan
INTEREST IN POLYCYSTIC OVARY SYNDROME (PCOS) has
increased recently with the realisation that this syndrome
involves far more than the reproductive system. Initially
called the Stein–Leve thal syndrome after its researchers in
the 1930s, PCOS is now recognised to be a metabolic
syndrom  whi h may include hyperinsulinaemia, hyper-
lipidaemia, diabetes mellitus, and p ssibly cardiac disease,
as well as the more conventionally recognised increase in
androgen levels, cosmetic problems, anovulation, infertility,
endometrial cancer and obesity.1,2
Diagnostic criteria
The diagnostic criteria for PCOS are controversial (Box 1),
but diagnosis is generally based on peripubertal onset of
menstrual problems with clinical or biochemical hyperan-
drogenism. The presence of polycystic ovaries on ultrasound
examination is particularly controversial as a criterion.
Polycystic ovaries are characterised by peripheral cysts (10
or more) less than 10 mm in size in an enlarged ovary with
significant increase in the central stroma4 (Box 2). However,
the ultrasound characteristics are subjective. Polycystic ova-
ries are also found in women with no evidence of menstrual
dysfunction or hyperandrogenism.5,6 As polycystic ovaries
arise through incomplete follicular development or failure of
ovulation, they may also occur in early to mid-adolescence,
and in women with bulimia, recovery from anorexia ner-
vosa, conditions of increased adrenal androgen production
and hyperprolactinaemia. Most publications on PCOS do
not include the presence of polycystic ovaries as a diagnostic
criterion.
Prevalence
Several studies have suggested a prevalence of PCOS of 5%–
10% in women of reproductive age, using the diagnostic
criteria of the US National Institutes of Health.7,8 Polycystic
ovaries alone were found in 20%–25% of women in surveys
in the United Kingdom and New Zealand.5,6 While women
with polycystic ovaries and no evidence of menstrual dys-
function or hyperandrogenism appear normal, they do have
an overexaggerated response to stimulation with gonado-
trophins such as follicle-stimulating hormone (FSH) in
cycles of assisted reproduction. PCOS is generally under-
diagnosed, and clinicians should remember that menstrual
abnormalities, such as cycles shorter than 21 days or longer
than 35 days, are often associated with the condition. Many
young women with these abnormalities are prescribed the
oral contraceptive pill, which masks the condition until they
try to achieve pregnancy.
Pathogenesis
The pathogenesis of PCOS is poorly understood, but the
primary defect may be insulin resistance leading to hyperin-
sulinaemia. In the ovary, the cardinal feature is functional
hyperandrogenism (Box 3). Circulating concentrations of
insulin and luteinising hormone (LH) are generally raised.
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ABSTRACT
■ Polycystic ovary syndrome (PCOS) is a common 
condition characterised by menstrual abnormalities and 
clinical or biochemical features of hyperandrogenism.
■ Features of PCOS may manifest at any age, ranging from 
childhood (premature puberty), teenage years (hirsutism, 
menstrual abnormalities), early adulthood and middle life 
(infertility, glucose intolerance) to later life (diabetes 
mellitus and cardiovascular disease).
■ While pelvic ultrasound examination is useful, many 
women without PCOS have polycystic ovaries; ultrasound 
evidence is not necessary for the diagnosis.
■ Testing for glucose intolerance and hyperlipidaemia is 
wise, especially in obese women, as diabetes mellitus is 
common in PCOS.
■ Lifestyle changes as recommended in diabetes are 
fundamental for treatment; addition of insulin-sensitising 
agents (eg, metformin) may be valuable in circumstances 
such as anovulatory infertility.
■ Infertility can be treated successfully in most women by 
diet and exercise, clomiphene citrate with or without 
metformin, ovarian drilling, or ovulation induction with 
gonadotrophins; in-vitro fertilisation should be avoided 
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The theca cells, which envelop the follicle and produce
androgens for conversion in the ovary to oestrogen, are over-
responsive to this stimulation. They increase in size and
overproduce androgens. The rise in LH levels is thought to
be caused by the relatively high and unchanging concentra-
tions of oestrogens that may alter the control of this
hormone by the hypothalamic–pituitary axis.
This combination of raised levels of androgens, oestrogen,
insulin and LH explains the classic PCOS presentation of
hirsutism, anovulation or dysfunctional bleeding, and dys-
function of glucose metabolism. Paradoxically, although the
insulin regulatory molecules on the theca cells are respon-
sive to insulin, those in the muscle and liver are resistant.
Manifestations of PCOS
PCOS is a lifelong condition which may have effects at all
ages, not just in the reproductive years (Box 4).
Fetal life. The condition may have its origins in fetal life,
with either intrauterine growth retardation or post-term
birth. Researchers have claimed that these children are more
prone to hyperinsulinism, premature pubarche and signs of
PCOS early in reproductive life.9,10
Teenagers will often have oligo- or amenorrhoea, hir-
sutism, acne and weight disorders. It is controversial
whether patients with PCOS suffer from a raised prevalence
of bulimia.
Women seeking to become pregnant will have difficulties
because of anovulation and later may be concerned about
overweight and hirsutism. It is controversial whether miscar-
riage is increased in PCOS, or whether pregnancy loss is a
result of excess body weight.
Endometrial hyperplasia and cancer
Menorrhagia is more common in PCOS because of lack of
ovulation and unopposed oestrogen action. The absence of
regular menstruation induced by progesterone withdrawal
may lead to endometrial hyperplasia and uncontrolled
bleeding. There is a theoretical risk of endometrial cancer.
Indeed, endometrial cancer has been alleged to be at least
four times more common in women with PCOS and may
appear in women as young as the early 20s. However, recent
studies have raised doubts about the validity of this
dogma.11
PCOS and the metabolic syndrome
Features of the metabolic syndrome, including obesity,
insulin resistance and dyslipidaemia, are common in women
with PCOS.
Obesity: The incidence of obesity in women with PCOS
varies between countries and ethnic groups. In the United
States, about 50% of women with PCOS are overweight or
obese, but this prevalence differs little from that in the
2: Polycystic ovaries
A: Polycystic ovaries, showing increased size and a smooth white surface reflecting thickening of the capsule.
B: Section through polycystic ovary, showing multiple cysts with diameter <10mm arranged around the periphery of the ovary. The stroma is 
increased, and the ovary enlarged.
1: Criteria for polycystic ovary syndrome and 
related disorders
Criteria of the US National Institutes of Health 3
Polycystic ovary syndrome
■ Presence of menstrual abnormalities and anovulation
■ Presence of clinical and/or biochemical hyperandrogenaemia
■ Absence of hyperprolactinaemia or thyroid disease
■ Absence of late-onset congenital adrenal hyperplasia
■ Absence of Cushing’s syndrome
Polycystic ovaries
■ Presence of polycystic ovaries on ultrasound examination
■ Absence of menstrual or cosmetic symptoms
■ Absence of biochemical hyperandrogenaemia
Idiopathic hirsutism
■ Presence of excess hair growth
■ Absence of biochemical hyperandrogenaemia
Proposed criteria (European Society of Human Reproduction and 
Embryology and American Society for Reproductive Medicine)*
Polycystic ovary syndrome is diagnosed if there are any two of the 
following:
■ Presence of polycystic ovaries on ultrasound examination
■ Clinical or biochemical hyperandrogenism
■ Menstrual dysfunction with anovulation
* As concluded at a ESHRE/ASRM-sponsored symposium on PCOS; 1 May 
2003; Rotterdam, The Netherlands.
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general community. In other countries, PCOS appears to be
associated with obesity, but at a lower rate than in the US.
Obesity tends to be central (abdominal) in its distribution,
and even lean women with PCOS may have a fat distribu-
tion favouring central omental and visceral fat (Box 5).
Insulin resistance: This is independently related to
PCOS, with women of normal weight with PCOS showing a
degree of hyperinsulinaemia and impaired glucose disposal
after meals and during glucose tolerance tests (oral or
intravenous).12 It is uncertain whether this insulin resistance
results from a specific genetic post-receptor defect, such as a
defect in serine phosphorylation,13 or whether it is compara-
ble to the problem seen in type 2 diabetes. Certainly,
hyperinsulinism is common but is difficult to interpret
clinically, given the fact that it also results from obesity.
Impaired glucose tolerance and type 2 diabetes: These
are major complications in overweight women with PCOS.
While fasting glucose level is usually normal, insulin release
after a glucose load is increased, and glucose disposal is
impaired. An excellent epidemiological study in the UK that
followed up women with a histological diagnosis of PCOS
after wedge resection of the ovaries found clear evidence of
an increase in the rate of diabetes.14 This confirmed the
results of many other studies from the US and Europe. In
obese women with PCOS, progression from normal glucose
function to impaired glucose tolerance or diabetes mellitus
is more rapid than in women without PCOS.15
Dyslipidaemia: Hypertriglyceridaemia, increased concen-
trations of low-density lipoprotein (LDL) cholesterol and
decreased concentrations of high-density lipoprotein (HDL)
cholesterol are common in women with PCOS, particularly
if obese. Levels of plasminogen activator inhibitor-1 may
also be raised, suggesting a chronic underlying inflamma-
tory-like process.
Cardiovascular disease: The metabolic features of PCOS
have led to widespread concern about the risk of cardiovas-
cular disease. A higher than expected prevalence of PCOS
has been reported among young women with angiographi-
cally proven narrowing of the coronary vessels; women with
PCOS were also more likely to have sonographic evidence of
premature obstruction of other large vessels.16,17 However, a
UK study of medical records and death certificates of
women with a histological diagnosis of PCOS revealed no
evidence for an increase in myocardial infarction or other
types of heart disease.14 The association is still under
investigation.
Investigations
History and general examination: These are required to
elicit evidence of peripubertal menstrual dysfunction and
hirsutism. Gynaecological examination is needed only to
exclude other causes of bleeding and miscarriage. Mild
clitoromegaly is not uncommon, but significant enlargement
raises the possibility of virilisation.
Pelvic ultrasound examination: Transvaginal ultrasound
is the best imaging mode. Transabdominal ultrasound
examination requires more expertise to get a good view,
particularly in obese women. Endometrial thickness should
always be assessed to exclude significant endometrial
pathology.
Hormone assays: There is ongoing debate about the
blood tests needed, if any. Diagnosis of PCOS demands the
exclusion of late-onset congenital adrenal hyperplasia
(measurement of 17-hydroxyprogesterone), thyroid abnor-
mality (thyroid-stimulating hormone), hyperprolactinaemia
(prolactin) and Cushing’s syndrome, but these tests can be
omitted if other features are not suggestive. Measurement of
testosterone (total or adjusted for sex-hormone-binding
globulin) is helpful to show hyperandrogenaemia and to rule
out an androgen-secreting tumour. Measurement of other
3: Ovarian defect in polycystic ovary syndrome
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androgens, such as dehydroepiandrosterone sulfate and
androstenedione, is not particularly useful.
Glucose testing: It is essential to exclude glucose intoler-
ance with glucose tolerance testing. It is doubtful whether
insulin measurement is indicated, as interpretation is
clouded by obesity. Some investigators have recommended
calculating an index of insulin resistance from glucose and
insulin levels (eg, the homeostasis model assessment
[HOMA] or quantitative insulin sensitivity check index
[QUICKI]).18
Because random and fasting glucose levels are usually
normal in women with PCOS, the standard Australian
recommendations for diagnosing diabetes by measuring
these levels are not applicable, and glucose tolerance testing
is recommended.19
Lipid status: Assessment of lipid status is justified (total
and HDL cholesterol and triglyceride levels).
Other investigations: Laparoscopy of the pelvis, com-
puted tomography and magnetic resonance imaging are
never justifiable for suspected PCOS alone. Endometrial
biopsy and hysteroscopy may be used to investigate unex-
plained vaginal bleeding.
Management
Management comprises treatment of the presenting symp-
toms, as well as any other abnormalities discovered on
investigation. The modality depends on the desire for
fertility.
Hirsutism
Hirsutism (Box 6) should be assessed qualitatively or semi-
quantified using the Ferriman–Gallwey score.20 Treatment
may include:
■ the oral contraceptive pill (eg, ethinyloestradiol 35 µg
plus cyproterone acetate 2 mg daily for 21 of 28 days);
■ cosmetic measures (eg, laser electrolysis, bleaching, wax-
ing or shaving);
■ oral oestrogen and cyproterone acetate (oestradiol valer-
ate 2 mg daily and cyproterone acetate 50 mg for 14 days a
month);
■ spironolactone (75–200 mg daily); or
■ other drugs, such as the antiandrogen flutamide or the
antifungal agent ketoconazole. These drugs either reduce
androgen production or inhibit androgen-binding to the
receptor. They are not in general use for this purpose in
Australia.
Response times for drugs can be up to 3 months.
Menstrual dysfunction and endometrial hyperplasia
Menstrual dysfunction, including irregular periods, can be
managed by administration of progestins (eg, medroxypro-
gesterone acetate or norethisterone) or the oral contracep-
tive pill.
Endometrial hyperplasia should be assessed by ultrasound
examination, endometrial biopsy or hysteroscopy, and can
be treated by hormonal therapy, such as the oral contracep-
tive pill or progestins (see case report, Box 7).
Overweight, obesity and glucose intolerance
Lifestyle changes are a first-line intervention in women with
PCOS who are overweight.21 Glucose intolerance can be
managed by diet and exercise, weight control and oral
antidiabetic drugs (eg, metformin).
Infertility
The cause of infertility in patients with PCOS is generally
lack of ovulation because of a failure of the follicles to
develop beyond 10 mm. Most cycles are anovulatory, and
induction of ovulation is essential.
Lifestyle modification: Several studies have shown that
weight loss can lead to resumption of ovulation within
weeks.22,23 Clark and colleagues demonstrated that even a
5% reduction in body mass restores ovulation and
fertility24,25 and devised a program of exercise and sensible
eating that has become a model across the world for treating
PCOS. Rapid changes in body composition and fat mass
can be shown during lifestyle change. High-protein diets
seem to be as effective as high-carbohydrate diets, provided
that fat and total calories are comparable.26 While lifestyle
changes are difficult to maintain, women seeking pregnancy
are highly motivated, making this a first-line intervention in
overweight women with PCOS.21,27 Longer-term changes in
weight are more difficult to maintain.
Clomiphene citrate: This is an oral oestrogen antagonist
that raises circulating concentrations of FSH and induces
follicular growth in most women with PCOS and anovula-
tion. The initial regimen is 25–50 mg per day for 5 days.
Therapy can be monitored by oestrogen levels, follicular
ultrasound examination and luteal progesterone level
(> 20 nmol/L). Failure of response is associated with high
body mass index and high androgen levels. Doses up to
200 mg per day can be used before failure of response is
5: Central obesity in polycystic ovary syndrome
Computed tomography of the abdomen in polycystic ovary 
syndrome, showing subcutaneous (S) and visceral (V) fat, 
surrounding bowel (B) and kidneys (K).
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established. In the rare situation in which side effects limit
treatment, tamoxifen can be used. Both treatments increase
the risk of multiple pregnancy.
Metformin: Use of the insulin-sensitising drug metformin at
doses of 500–2500mg daily is controversial, but appears valua-
ble in increasing menstrual cyclicity and pregnancy rate.28-31 A
recent consensus statement from the Endocrine Society of
Australia indicated its use in women trying to become preg-
nant.28 Recent systematic reviews suggest that the drug has
efficacy for ovulation induction, either as a sole agent or in
combination with clomiphene citrate.29 It has been widely used
for this purpose, and no specific neonatal complications have
been described, despite it being classed as “category C” in
Australia (drugs which have caused or may be suspected of
causing harmful effects on the human fetus). There is inade-
quate evidence at present to suggest its use in pregnancy to
prevent gestational diabetes or recurrent miscarriage.
The new insulin-sensitising agents, the “glitazones” —
troglitazone (now discontinued), rosiglitazone and pioglita-
zone — have been shown to be very effective for ovulation
induction,32 but are not approved by the Pharamaceutical
Benefits Scheme for PCOS. There is greater concern about
the effects on the fetus of these drugs compared with
metformin, and they should not be used by women trying to
become pregnant.33
Surgery to the ovaries: Wedge resection of the ovaries has
been abandoned because of concerns about pelvic adhe-
sions, another cause of subfertility, and loss of valuable
ovarian tissue. Ovarian diathermy or laser drilling has been
used in recent years with apparently good results; a recent
systematic review comparing drilling with clomiphene cit-
rate and gonadotrophins proved equivalence in the studies
examined.34 However, like wedge resection, this surgery
may produce pelvic adhesions. Destructive surgery to the
ovary should be used only after extensive discussion with the
patient and not because the ovaries are found to be poly-
cystic incidentally during routine laparoscopy.
Gonadotrophin treatment: Ovulation induction with
gonadotrophins such as FSH has proved successful for at
least three decades, but demands skill and experience to
avoid multiple pregnancies and ovarian hyperstimulation
syndrome. Patients start on low-dose recombinant FSH
administered subcutaneously. Monitoring of ovarian
response involves ultrasound examination, often with
oestradiol measurement. Human chorionic gonadotrophin
is given when one follicle reaches 16–20 mm in size. Any
more than two follicles of an appropriate size gives the risk
of multiple pregnancies. Multiple gonadotrophin cycles may
be required to achieve pregnancy, but this approach is
preferable before more invasive procedures, such as in-vitro
fertilisation.
7: Case report — a missed diagnosis 
Presentation: A 26-year-old obese single woman presented with 
severe menstrual bleeding requiring blood transfusion and 
emergency hormone therapy with progestins.
History: She had reached menarche at age 11 years and had 
irregular periods throughout her teenage years, with menstrual 
cycles ranging from 6 weeks to 6 months. Menstruation, when it 
occurred, lasted for up to 4 weeks with heavy clots, and caused 
fatigue and weakness. She had been admitted to hospital for 
blood transfusion on three occasions. She complained of 
hirsutism around the face and lower abdomen and weight gain 
from the age of 13 years. Two dilatation and curettages a year 
before had revealed only proliferative endometrium. She had 
never used regular hormone therapy, such as the oral 
contraceptive pill or progestins.
Investigations: She had significant iron deficiency anaemia 
(haemoglobin level, 80 g/L; reference range [RR], 115–165 g/L). 
Tests for clotting abnormalities and thrombophilias gave normal 
results. Measurement of serum hormone levels showed a raised 
level of testosterone (3.5 nmol/L; RR, 0.5–1.8 nmol/L), low level of 
sex hormone binding globulin (15 nmol/L; RR, 20–80 nmol/L), and 
normal levels of prolactin (300 mIU/L; RR, 150–450 mIU/L) and 
thyroid-stimulating hormone (2.2 mIU/L; RR, 0.5–4.0 mIU/L). 
Glucose tolerance testing showed glucose intolerance (2-h 
glucose level after 75 g glucose load, 10.5 mmol/L). Transvaginal 
pelvic ultrasound examination showed enlarged polycystic 
ovaries (ovarian volumes, 12 mL and 15 mL; multiple peripheral 
cysts < 10 mm on the periphery of the ovaries; and increased 
ovarian stromal echo) and an enlarged uterus (endometrium, 
20 mm). Endometrial biopsy showed proliferative endometrium 
only.
Management: She was treated with medroxyprogesterone 
acetate (30 mg daily for 2 weeks each month) with minimal 
response.
Six months later, she had an episode of severe bleeding requiring 
hospital admission. Hysteroscopy and biopsy revealed extensive 
cystic glandular endometrial hyperplasia with adenomatous 
changes suggesting an unacceptable risk of malignancy, 
which necessitated subsequent hysterectomy with ovarian 
conservation.
■ Polycystic ovary syndrome (PCOS) could have been
diagnosed soon after menarche if her practitioner had been
more aware of how common this condition is in teenagers.
Management of abnormal cycles with prophylactic pro-
gestins or the oral contraceptive pill to prevent endometrial
hyperplasia would have been appropriate.
■ Endometrial hyperplasia is more common in young
women with PCOS, and ongoing bleeding requires hysteros-
copy rather than blind curettage or endometrial biopsy.
■ This woman will probably have significant insulin resist-
ance. Ongoing surveillance for diabetes mellitus is required,
and she should modify her diet and increase exercise.
6: Skin manifestations of polycystic ovary syndrome
Young woman with PCOS showing facial hirsutism (A) and axillary 
acanthosis nigricans (B). The latter is associated with severe insulin 
resistance and hyperinsulinaemia and is an occasional finding in 
PCOS (photographs courtesy Dr John Casey, St Vincent’s Clinic, 
Sydney, NSW).
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In-vitro fertilisation: Provided there is no problem other
than anovulation, this has little place in the management of
infertility resulting from PCOS. Ovulation induction by a
skilled reproductive endocrinologist is preferable to in-vitro
fertilisation because of the risks of hyperstimulation and
multiple pregnancy with the latter procedure.
Long-term management
Women with PCOS require ongoing surveillance to detect
impaired glucose tolerance, hyperlipidaemia, endometrial
hyperplasia and consequent complications. Obese women, in
particular, require regular (possibly annual) glucose tolerance
testing because of the potential for rapid progression from
normal to impaired glucose tolerance and diabetes.15
Some investigators have suggested prophylactic use of
metformin in young teenagers and older women to avoid the
problems of the metabolic syndrome. This approach is
probably premature at present and is not recommended.
Advice about improved exercise and diet is more rational,
given the abundant data on the role of lifestyle change in
preventing and treating problems of glucose metabolism.
Useful Internet resources for patients are shown in Box 8.
Referral
The diagnosis of PCOS may prove difficult in a few cases,
and referral to a medical or reproductive endocrinologist
may be valuable. Most gynaecologists have experience of
using clomiphene citrate, but referral to an infertility expert
is best when gonadotrophins are needed. Most patients with
PCOS can be diagnosed and managed in general practice.
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8: Useful Internet resources for patients
www.pcosupport.org (US Polycystic Ovarian Syndrome Association)
www.posaa.asn.au (Polycystic Ovarian Syndrome Association of 
Australia)
www.menopause.net.au (Adelaide Hormone & Menopause Centre)
www.jeanhailes.org.au (Jean Hailes Foundation)
